Gly­coMimet­ics shares crash af­ter Pfiz­er team dis­miss­es their lead drug as a PhI­II fail­ure

Close to 8 years ago, the BD team at Pfiz­er signed a $340 mil­lion deal to li­cense in a mid-stage drug from Gly­coMimet­ics for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.